Abstract 11P
Background
Adjuvant treatment has become more personalized in resectable NSCLC. New biomarkers are needed to predict treatment outcomes. In this study, we looked for a broadly applicable biomarker using deep learning on hematoxylin and eosin (H&E) histology. Based on recommendations [Salgado et al., Ann Oncol 2015], we focused on analyzing tumor infiltrating lymphocytes in the stromal (sTILs) and the intratumoral (iTILs) compartment. We assessed TILs fully automated at slide and tumor bulk level, guided by manual annotations of the tumor bulk. We hypothesized high iTIL and sTIL density being associated with improved disease-free survival (DFS) in the total study population.
Methods
In this retrospective cohort study, 106 chemo-naive patients with resectable NSCLC were identified in two cohorts, based on recurrence (n=45, cohort A) versus no recurrence (n=61, cohort B). Whole mount tumor slides were stained with H&E and digitalized. Deep learning models were used to compute tissue masks [J. Spronck et al., PLMR 2023] and for TIL detection [HoverNet, Med Imag Anal. 2019]. Tumor bulk was manually annotated to exclude distant tumor lets. Distribution of iTIL and sTIL densities in cohort A and B were compared using Mann-Whitney U based on absence of normal distribution patterns. DFS was measured by log-rank and cox regression to correct for covariates after a binary distinction based on median TIL densities.
Results
The slide and annotation iTIL density were significantly higher in cohort B versus cohort A (slide: 300 vs 232 TILs/mm2, p=0.007 and annotation: 318 vs 230 TILs/mm2, p=0.013). The slide and annotation sTIL density were also higher in cohort B versus A (slide: 1489 vs 1153 TILs/mm2, p=0.035 and annotation: 1753 vs 1469, p=0.030). DFS was significantly higher in patients with a high slide iTIL density compared to patients with a low slide iTIL density (HR 0.44; 95% CI 0.24 to 0.81; P<0.009). DFS remained significant after correction for age, gender, smoking history co-morbidity and clinical stage, but not for ECOG performance.
Conclusions
The iTIL density detected on slide level could serve as favorable prognostic factor in patients with resectable NSCLC, potentially being a biomarker for adjuvant treatment.
Legal entity responsible for the study
The authors.
Funding
NWO/VIDI.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
156P - Liver Metastases Correlate with Shortened Survival and Increased Dissociate Response in Patients Treated with T-Cell Engagers.
Presenter: Noé Herbel
Session: Poster Display session
157P - Preliminary results of a multicentric randomized phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)
Presenter: Caroline Even
Session: Poster Display session
158P - XCR1+ dendritic cell (DC) role in antitumoral response to anti PD-L1 antibody: Data from the phase Ib/II trial of DC vaccination in small cell lung cancer patients
Presenter: Maria Gonzalez Cao
Session: Poster Display session
159P - Unveiling the impact of DC vaccination on systemic immunity in advanced malignant melanoma: Preliminary results from the ABSIDE study
Presenter: Giada Sabatino
Session: Poster Display session
160P - Oral DNA vaccination targeting personalised neoantigens in immune checkpoint-inhibitor treated solid tumor patients: Interim results
Presenter: Domas Vaitiekus
Session: Poster Display session
161P - Safety of TrimelVax vaccine for patients with advanced melanoma: Clinical results
Presenter: ROBERTO ESTAY
Session: Poster Display session
162P - EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)
Presenter: Romain Cohen
Session: Poster Display session
163P - Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors
Presenter: Elise Jirovec
Session: Poster Display session
164P - Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster Display session
165P - TIGIT inhibition in non-small cell lung cancer: Meta-analysis of clinical efficacy and biomarker correlation
Presenter: Hashim Talib Hashim
Session: Poster Display session